Is Collplant Biotechnologies Stock a Good Investment?
Collplant Biotechnologies Investment Advice | CLGN |
- Examine Collplant Biotechnologies' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Collplant Biotechnologies' leadership team and their track record. Good management can help Collplant Biotechnologies navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Collplant Biotechnologies' business and its evolving consumer preferences.
- Compare Collplant Biotechnologies' performance and market position to its competitors. Analyze how Collplant Biotechnologies is positioned in terms of product offerings, innovation, and market share.
- Check if Collplant Biotechnologies pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Collplant Biotechnologies' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Collplant Biotechnologies stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Collplant Biotechnologies is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Collplant Biotechnologies Stock
Researching Collplant Biotechnologies' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was currently reported as 1.48. The company recorded a loss per share of 1.53. Collplant Biotechnologies last dividend was issued on the 21st of November 2016. The entity had 2:3 split on the 21st of November 2016.
To determine if Collplant Biotechnologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Collplant Biotechnologies' research are outlined below:
| Collplant Biotechnologies generated a negative expected return over the last 90 days | |
| Collplant Biotechnologies has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 10.96 M. Net Loss for the year was (7.02 M) with loss before overhead, payroll, taxes, and interest of (1.48 M). | |
| Collplant Biotechnologies currently holds about 36.29 M in cash with (2.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.27. | |
| Collplant Biotechnologies has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia |
Collplant Biotechnologies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Collplant Biotechnologies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Collplant Biotechnologies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 22nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Collplant Biotechnologies' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Collplant Biotechnologies' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2019-04-01 | 2019-03-31 | 0.011 | 0.0055 | -0.0055 | 50 | ||
2023-05-24 | 2023-03-31 | -0.29 | -0.33 | -0.04 | 13 | ||
2020-08-28 | 2020-06-30 | -0.15 | -0.2 | -0.05 | 33 | ||
2023-03-29 | 2022-12-31 | -0.31 | -0.38 | -0.07 | 22 | ||
2022-12-01 | 2022-09-30 | -0.31 | -0.4 | -0.09 | 29 | ||
2024-11-27 | 2024-09-30 | -0.28 | -0.38 | -0.1 | 35 | ||
2024-08-20 | 2024-06-30 | -0.27 | -0.37 | -0.1 | 37 | ||
2021-03-26 | 2020-12-31 | -0.3 | -0.42 | -0.12 | 40 |
Collplant Biotechnologies Target Price Consensus
Collplant target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Collplant Biotechnologies' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Strong Buy |
Most Collplant analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Collplant stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Collplant Biotechnologies, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCollplant Biotechnologies Target Price Projection
Collplant Biotechnologies' current and average target prices are 3.30 and 12.50, respectively. The current price of Collplant Biotechnologies is the price at which Collplant Biotechnologies is currently trading. On the other hand, Collplant Biotechnologies' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Collplant Biotechnologies Market Quote on 25th of February 2025
Target Price
Analyst Consensus On Collplant Biotechnologies Target Price
Collplant Biotechnologies Analyst Ratings
Collplant Biotechnologies' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Collplant Biotechnologies stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Collplant Biotechnologies' financials, market performance, and future outlook by experienced professionals. Collplant Biotechnologies' historical ratings below, therefore, can serve as a valuable tool for investors.Know Collplant Biotechnologies' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Collplant Biotechnologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Collplant Biotechnologies backward and forwards among themselves. Collplant Biotechnologies' institutional investor refers to the entity that pools money to purchase Collplant Biotechnologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Parallel Advisors, Llc | 2024-12-31 | 3.3 K |
Collplant Biotechnologies' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.34 M.Market Cap |
|
Collplant Biotechnologies' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.22) | (0.23) | |
| Return On Assets | (0.21) | (0.19) | |
| Return On Equity | (0.22) | (0.23) |
Determining Collplant Biotechnologies' profitability involves analyzing its financial statements and using various financial metrics to determine if Collplant Biotechnologies is a good buy. For example, gross profit margin measures Collplant Biotechnologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Collplant Biotechnologies' profitability and make more informed investment decisions.
Collplant Biotechnologies' Earnings Breakdown by Geography
Evaluate Collplant Biotechnologies' management efficiency
Collplant Biotechnologies has return on total asset (ROA) of (0.3822) % which means that it has lost $0.3822 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7065) %, meaning that it created substantial loss on money invested by shareholders. Collplant Biotechnologies' management efficiency ratios could be used to measure how well Collplant Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of February 2025, Return On Tangible Assets is likely to drop to -0.2. In addition to that, Return On Capital Employed is likely to drop to -0.23. At this time, Collplant Biotechnologies' Total Assets are very stable compared to the past year. As of the 25th of February 2025, Other Current Assets is likely to grow to about 283.1 K, while Non Current Assets Total are likely to drop about 3.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.86 | 2.77 | |
| Tangible Book Value Per Share | 2.84 | 2.59 | |
| Enterprise Value Over EBITDA | (6.92) | (6.57) | |
| Price Book Value Ratio | 2.31 | 2.20 | |
| Enterprise Value Multiple | (6.92) | (6.57) | |
| Price Fair Value | 2.31 | 2.20 | |
| Enterprise Value | 44.3 M | 59.3 M |
At Collplant Biotechnologies, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 0.627 |
Basic technical analysis of Collplant Stock
As of the 25th of February, Collplant Biotechnologies shows the Risk Adjusted Performance of (0.07), mean deviation of 2.24, and Standard Deviation of 3.1. Collplant Biotechnologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Collplant Biotechnologies' Outstanding Corporate Bonds
Collplant Biotechnologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Collplant Biotechnologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Collplant bonds can be classified according to their maturity, which is the date when Collplant Biotechnologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Collplant Biotechnologies' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Collplant Biotechnologies' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (1.28) | |||
| Mean Deviation | 2.24 | |||
| Coefficient Of Variation | (933.96) | |||
| Standard Deviation | 3.1 | |||
| Variance | 9.63 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.32) | |||
| Treynor Ratio | (1.29) | |||
| Maximum Drawdown | 17.19 | |||
| Value At Risk | (5.84) | |||
| Potential Upside | 4.5 | |||
| Skewness | 0.3909 | |||
| Kurtosis | 1.86 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (1.28) | |||
| Mean Deviation | 2.24 | |||
| Coefficient Of Variation | (933.96) | |||
| Standard Deviation | 3.1 | |||
| Variance | 9.63 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.32) | |||
| Treynor Ratio | (1.29) | |||
| Maximum Drawdown | 17.19 | |||
| Value At Risk | (5.84) | |||
| Potential Upside | 4.5 | |||
| Skewness | 0.3909 | |||
| Kurtosis | 1.86 |
Consider Collplant Biotechnologies' intraday indicators
Collplant Biotechnologies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Collplant Biotechnologies stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Collplant Biotechnologies Corporate Filings
6K | 24th of February 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 28th of January 2025 Other Reports | ViewVerify |
Collplant Stock media impact
Far too much social signal, news, headlines, and media speculation about Collplant Biotechnologies that are available to investors today. That information is available publicly through Collplant media outlets and privately through word of mouth or via Collplant internal channels. However, regardless of the origin, that massive amount of Collplant data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Collplant Biotechnologies news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Collplant Biotechnologies relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Collplant Biotechnologies' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Collplant Biotechnologies alpha.
Collplant Biotechnologies Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Collplant Biotechnologies can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Collplant Biotechnologies Corporate Management
| Oren Fahimipoor | Vice Operations | Profile | |
| Michal Roytman | VP Marketing | Profile | |
| Pr Shoseyov | Founder Scientist | Profile | |
| Eran CPA | Deputy CFO | Profile | |
| Elana Gazal | Vice Development | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share | Quarterly Revenue Growth (0.91) | Return On Assets | Return On Equity |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Collplant Biotechnologies' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.